Skip to search.
 FTSE 100 Down 1.37%

KaloBios Pharmaceuticals, Inc. (KBIO)

-NasdaqGM
0.48 Down 0.03(4.95%) 26 Mar 20:00
Add to Portfolio
Prev Close:0.51
Open:0.48
Bid:0.47 x 10000
Ask:0.56 x 5100
1y Target Est:5.00
Beta:4.49
Earnings Date:6 May - 11 May (Est.)
Day's Range:0.47 - 0.50
52wk Range:0.36 - 2.80
Volume:566,165
Avg Vol (3m):1,458,260
Market Cap:15.84m
P/E (ttm):N/A
EPS (ttm):-1.15
Div & Yield:N/A (N/A)
Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

  • No Headlines available for KBIO at this time.

Comparison

Symbol% ChgMkt Cap
KBIODown 4.95%15.84m
VRTXDown 0.88%28.47b

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-15) :-1.34
Quarterly EPS Est (Mar-15) :-0.30
Mean Recommendation*:2.3
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback